Senores Pharma Q1 FY27: Revenue Up 36% to ₹180 Cr, PAT Rises 56% to ₹31 Cr
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180.21 crore, up 35.9% YoY. PAT increased 56% to ₹30.45 crore. EBITDA grew 87% to ₹54 crore. Regulated markets revenue rose 41.9% to ₹127.8 crore. Ms. Anjali Shah appointed as Senior Management Personnel.
The strong financial performance, particularly the significant revenue and profit growth, coupled with margin expansion, is expected to have a considerable positive impact on the company's stock.
The company reported strong year-on-year growth in revenue and profit, along with significant margin expansion. The appointment of a new SMP also adds to the positive outlook.
Senores Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported consolidated revenue of ₹180.21 crore, a year-on-year increase of 35.9%, driven by strong growth in regulated and emerging markets.
Consolidated profit after tax (PAT) for the quarter stood at ₹30.45 crore, marking a significant increase of 56% compared to the same period last year. EBITDA also saw a substantial rise of 87% to ₹54 crore, with margins expanding by approximately 800 basis points.
The company highlighted robust performance in regulated markets, with revenue growing by 41.9% to ₹127.8 crore, supported by an expanded product portfolio of 58 approved ANDAs. Emerging markets contributed ₹37.6 crore in revenue, a 29.6% increase year-on-year, with EBITDA margins around 14%.
In a significant development, Ms. Anjali Shah has been appointed as Senior Management Personnel (SMP) effective July 27, 2026. She is a Chartered Accountant with over 10 years of experience in finance and related functions.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.